Interstitial cystitis (IC), also known as painful bladder syndrome, is a chronic condition causing bladder pressure, pain, and pelvic discomfort. According to the CDC, it accounts for around 1% of the U.S. population. The interstitial cystitis drug pipeline includes a range of therapeutics targeting inflammation, bladder repair, and pain management. With a growing focus on personalized medicine and non-opioid pain relief, the demand for advanced interstitial cystitis therapeutics is expected to rise. According to the interstitial cystitis pipeline analysis by Expert Market Research, increasing R&D investments and emerging biologics are projected to drive market growth in the coming years.
Major companies involved in the interstitial cystitis pipeline analysis include Vaneltix Pharma, Inc., Ono Pharmaceutical Co. Ltd., and others.
Leading drugs currently in the pipeline include VNX001, ONO-1110, and others.
Increasing clinical trials, rising cases of bladder pain syndrome, and progress in targeted anti-inflammatory therapies are driving strong development across the interstitial cystitis drug pipeline.
The Interstitial Cystitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into interstitial cystitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for interstitial cystitis. The interstitial cystitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The interstitial cystitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with interstitial cystitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to interstitial cystitis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It occurs when the bladder lining becomes damaged or inflamed, allowing urine irritants to penetrate and aggravate the bladder wall. The exact cause remains unknown, but it may involve autoimmune, allergic, or neurological factors.
Interstitial cystitis treatment focuses on symptom relief and may include oral medications, bladder instillations, physical therapy, and dietary modifications, depending on severity and patient response. Pentosan Polysulfate Sodium (Elmiron), the only FDA-approved oral drug for IC/BPS, remains a key treatment option. It helps in repairing the bladder’s protective lining, and reducing irritation along with pain.
The interstitial cystitis (IC) drug pipeline is expanding in response to significant global disease burden. According to the Centers for Disease Control and Prevention (CDC), IC affects approximately 1% of the U.S. population. In India, recent studies indicate that 37% of individuals experience urinary tract infections regularly. Women face a higher incidence, with up to 12% affected annually and 5–10% of pregnant women experiencing infections during pregnancy.
This section of the report covers the analysis of interstitial cystitis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total interstitial cystitis clinical trials, at 58%, reflecting strong ongoing clinical development in the interstitial cystitis drug pipeline. Phase I follows with 25%, indicating growing early-stage research. These advancements signal promising innovation and future treatment potential in the interstitial cystitis market.
The drug molecule categories covered under the interstitial cystitis pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapies. The interstitial cystitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for interstitial cystitis. Nociceptin receptor-targeting agents are emerging as novel therapies for interstitial cystitis. For instance, sunobinop, an oral compound that activates the nociceptin/orphanin-FQ peptide receptor, is under clinical evaluation. In a phase 1b study, sunobinop demonstrated potential in reducing bladder pain and urinary symptoms, offering a new class of treatment for this chronic condition.
The EMR report for the interstitial cystitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed interstitial cystitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in interstitial cystitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for interstitial cystitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of interstitial cystitis drug candidates.
Vaneltix Pharma, Inc., is evaluating VNX001 in Phase 2 clinical studies for treating interstitial cystitis/bladder pain syndrome (IC/BPS). The ongoing study is assessing the safety, efficacy, and frequency of intravesical VNX001 administration. This drug, a novel combination of heparin sodium and lidocaine hydrochloride, is being delivered via catheter to reduce moderate to severe acute bladder pain. The objective is to determine optimal PRN dosing over 14 days.
ONO-1110 is currently undergoing a Phase IIa clinical trial sponsored by Ono Pharmaceutical Co. Ltd, targeting Hunner Type interstitial cystitis. The study is evaluating the efficacy and safety of ONO-1110, a novel drug regulating endogenous cannabinoids. Unlike cannabis-based treatments, ONO-1110 is designed to deliver the therapeutic benefits of cannabinoids without central side effects like euphoria. The trial is aiming to demonstrate proof of concept in approximately 50 patients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Interstitial Cystitis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for interstitial cystitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into interstitial cystitis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share